AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa
Phase 4
Completed
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Genetic: EGFR Mutation TestGenetic: Ki-67 protein expression
- First Posted Date
- 2009-10-23
- Last Posted Date
- 2010-05-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 59
- Registration Number
- NCT01000740
- Locations
- 🇨🇳
Research Site, Hangzhou, Zhejiang, China
Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients
- First Posted Date
- 2009-10-22
- Last Posted Date
- 2012-07-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 26
- Registration Number
- NCT00999882
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Republic of
A Study Evaluating the Treatment Selection and Outcome When Changing Antipsychotic Treatment in Schizophrenic Patients
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2009-10-22
- Last Posted Date
- 2011-02-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 574
- Registration Number
- NCT00999895
- Locations
- 🇬🇷
Research Site, Serres, Greece
Prevalence of Gastroesophageal Reflux Disease (GERD) in Patients With Upper Gastrointestinal Track (GIT) Symptoms in Thailand
Completed
- Conditions
- Upper GIT Symptoms
- First Posted Date
- 2009-10-21
- Last Posted Date
- 2011-03-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4108
- Registration Number
- NCT00999063
- Locations
- 🇹🇭
Research Site, Maung, Uttaradit, Thailand
The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen
- First Posted Date
- 2009-10-21
- Last Posted Date
- 2016-02-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 60
- Registration Number
- NCT00999466
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
Dyslipaemia, Atherosclerosis Risk and Increased hsCRP and Inflammatory and Oxidative Status in the Spanish Population. Database Analysis of Previous Studies Performed in Spain
Completed
- Conditions
- Inflammatory and Oxidative Status in the Spanish PopulationAtherosclerosis RiskDyslipaemiaIncreased hsCRP
- First Posted Date
- 2009-10-20
- Last Posted Date
- 2011-10-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30181
- Registration Number
- NCT00998062
- Locations
- 🇪🇸
Research Site, Navarra, Spain
10mg ZD4054 (Zibotentan) PK Study in Male, Elderly Chinese Patients With Advanced Solid Malignancies
Phase 1
Completed
- Conditions
- Advanced Solid Malignancies
- Interventions
- Drug: ZD4054 (Zibotentan)
- First Posted Date
- 2009-10-20
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 15
- Registration Number
- NCT00997945
- Locations
- 🇨🇳
Research Site, Shanghai, Shanghai, China
Study Comparing Esomeprazole and Acetylsalicylic Acid (ASA) Combined Together as One Capsule Versus These Medications Taken Separately
Phase 1
Completed
- Conditions
- Peptic Ulcer Disease
- Interventions
- First Posted Date
- 2009-10-20
- Last Posted Date
- 2010-12-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 138
- Registration Number
- NCT00998075
- Locations
- 🇨🇦
Research Site, Scarborough, Ontario, Canada
Epidemiological and Scientific Evaluation of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or m
Completed
- Conditions
- Newly Diagnosed Locally Advanced or Metastatic Non-small Cell Lung Cancer
- First Posted Date
- 2009-10-19
- Last Posted Date
- 2013-10-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 4243
- Registration Number
- NCT00997230
- Locations
- 🇩🇪
Research Site, Zusmarshausen, Germany
A Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD1446 Administered for 4 Weeks in Elderly Healthy Volunteers
- First Posted Date
- 2009-10-19
- Last Posted Date
- 2010-01-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 97
- Registration Number
- NCT00997308
- Locations
- 🇸🇪
Research, Lund, Sweden